Ondexxya - direct healthcare professional communication (DHPC)

andexanet alfa

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization

Key facts

• Medicine name:
  Ondexxya
• Active substance:
  andexanet alfa
• Therapeutic area (MeSH):
  Drug-Related Side Effects and Adverse Reactions
• Procedure number:
  EMEA/H/C/004108/II/0011
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  V03AB
• Dissemination date:
  04/11/2020